David Lebovitz
Stock Analyst at Citigroup
(3.21)
# 1,058
Out of 4,918 analysts
90
Total ratings
66.15%
Success rate
7.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $364 → $404 | $401.80 | +0.55% | 32 | Jul 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $58.14 | +34.16% | 4 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $302.17 | +55.21% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $27.84 | +165.80% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $52.02 | -26.95% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $52.13 | -67.39% | 5 | Oct 27, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $88.28 | -38.83% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $43.03 | -18.66% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.58 | +975.95% | 11 | Apr 30, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $12 → $11 | $0.77 | +1,325.98% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $174.28 | +14.18% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $3.95 | +12,051.90% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Jul 11, 2025
Maintains: Buy
Price Target: $364 → $404
Current: $401.80
Upside: +0.55%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $58.14
Upside: +34.16%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $302.17
Upside: +55.21%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $27.84
Upside: +165.80%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $52.02
Upside: -26.95%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $52.13
Upside: -67.39%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $88.28
Upside: -38.83%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $43.03
Upside: -18.66%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.58
Upside: +975.95%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.77
Upside: +1,325.98%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $174.28
Upside: +14.18%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $3.95
Upside: +12,051.90%